US03168L1052
US03168L1052
Amneal Pharmaceuticals, Inc.
Loading chart...
Elevated Business & Solvency Risk
Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 40/100).
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 1.2x as much as the broader market.
Beta (Market Relation)
1.22x
Above averageVolatility (5Y p.a.)
50.5% p.a.
5-Year HorizonMax Drawdown (5Y)
-78.3%
5-Year HorizonSharpe Ratio
0.51
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +87.5% |
| 3 Years | 39.7% | -24.6% | 1.7 | +69.9% |
| 5 Years | 50.5% | -78.3% | 0.51 | +28.4% |
| 10 Years | 63.3% | -94.8% | 0.01 | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 2387%.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (50.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -94.8% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
4 ISS Score: 4 / 10
Audit Risk
3 ISS Score: 3 / 10
Board Risk
8 ISS Score: 8 / 10
Short Ratio
7.16